Allogene Therapeutics (ALLO) has been cleared by US regulators to begin phase 1 testing of its ALLO-329 drug candidate in patients with systemic lupus erythematosus.
The upcoming study approved by the US Food and Drug Administration and slated to begin by mid-2025 takes in several types of rheumatological disorders and will evaluate the safety and efficacy of ALLO-329 in patients with lupus nephritis, idiopathic inflammatory myopathies and systemic sclerosis.
The trial design also is intended to increase CAR-T cell expansion in patients and prevent rejection by having two distinct lymphodepletion arms, with patients in one part of the study receiving a dose of cyclophosphamide alone which is used by rheumatologists and the other that eliminates lymphodepletion entirely, the company said.
Allogene shares were 0.3% lower in recent trading.
Price: 1.95, Change: +0.02, Percent Change: +0.78
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。